Dornase alfa therapy in cystic fibrosis: Who should get it?

Chest

Volumn 110, Issue 4, 1996, Pages 871-872

  Kanga, J F ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DORNASE ALFA; EXPECTORANT AGENT; MUCOLYTIC AGENT; PLACEBO;

AEROSOL; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EDITORIAL; FEVER; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG FIBROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RHINITIS;

EID: 0029970702     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.110.4.871     Document Type: Editorial

References (9)

1. Liberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis JAMA 98 1968 597 598
2. Shak S Capon DJ Hellniss R Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum Proc Natl Acad Sci USA 87 1990 9188 9192
3. Hubbard RC McElvaney NG Birrer P A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis N Engl J Med 326 1992 812 815
4. Aitken ML Burke W McDonald G Recombinant human DNase inhaled in normal subjects and patients with cystic fibrosis JAMA 267 1992 1947 1951
5. Ranasinha C Assoufi B Shak S Efficacy and safety of short-term administration of aerosolized recombinant human DNase (rhDNase) in adults with stable stage cystic fibrosis Lancet 342 1993 199 202
6. Ramsey BW Astley SW Aitken ML Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis Am Rev Respir Dis 148 1994 145 151
7. Fuchs HJ Borowitz DS Christiansen DH Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis N Engl J Med 331 1994 637 642
8. Shah PL Scott SF Hodson ME. Report on a multi-centre study using aerosolized recombinant human DNase I in the treatment of cystic fibrosis patients with severe pulmonary disease [abstract] Pediatr Pulmonol Suppl 9 1993 157 158
9. Wilmott R Amin RS Collin A A phase II, double-blind, multi-center study of the safety and efficacy of aerosolized recombinant DNase I (rh DNase) in hospitalized patients with CF experiencing acute pulmonary exacerbations [abstract] Pediatr Pulmonol Suppl 9 1993 154